Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non-myeloablative drug combination
暂无分享,去创建一个
T. Masszi | P. Reményi | E. Kelemen | A. Barta | K. Pálóczi
[1] A. Chase,et al. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse , 1997, British journal of haematology.
[2] F. Uher,et al. Comparison of the lymphoid toxicities of mitobronitol and busulphan in mice: reduced B cell toxicity and improved thymic recovery as possible contributors to the reduced risk for complications following BMT with mitobronitol preconditioning , 1997, Leukemia.
[3] A Ferrant,et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.
[4] R. Clift. Marrow transplantation for chronic myeloid leukemia. , 1995, Cancer treatment and research.
[5] P. Ljungman,et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. , 1994, Blood.
[6] G. Váradi,et al. Non-supralethal mitobronitol/cytarabine/cyclophosphamide conditioning without irradiation before bone marrow transplantation for accelerated chronic granulocytic leukemia: apparent absence of acute graft-versus-host disease. , 1993, Leukemia.